



## Monaldi Archives for Chest Disease

eISSN 2532-5264

<https://www.monaldi-archives.org/>

**Publisher's Disclaimer.** E-publishing ahead of print is increasingly important for the rapid dissemination of science. The **Early Access** service lets users access peer-reviewed articles well before print / regular issue publication, significantly reducing the time it takes for critical findings to reach the research community. These articles are searchable and citable by their DOI (Digital Object Identifier).

The **Monaldi Archives for Chest Disease** is, therefore, e-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear in a regular issue of the journal.

E-publishing of this PDF file has been approved by the authors.

*All legal disclaimers applicable to the journal apply to this production process as well.*

Monaldi Arch Chest Dis 2024 [Online ahead of print]

*To cite this Article:*

Gupta A, Chandra E, Anand S, et al. **Latent tuberculosis diagnostics: current scenario and review.** *Monaldi Arch Chest Dis* doi: 10.4081/monaldi.2024.2984

 ©The Author(s), 2024  
Licensee [PAGEPress](#), Italy

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.



## **Latent tuberculosis diagnostics: current scenario and review**

Amitesh Gupta,<sup>1</sup> Eshutosh Chandra,<sup>1</sup> Shipra Anand,<sup>1</sup> Naresh Kumar,<sup>1</sup> Richa Arora,<sup>1</sup>  
Divyanshi Rana,<sup>1</sup> Parul Mrigpuri<sup>2</sup>

<sup>1</sup>Department of Pulmonary Medicine, Maulana Azad Medical College and associated Lok Nayak Hospital, New Delhi; <sup>2</sup>Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, India

**Correspondence:** Amitesh Gupta, Department of Pulmonary Medicine, Maulana Azad Medical College and associated Lok Nayak Hospital, New Delhi - 110002, India.

Tel.: 91-8826687283.

E-mail: amiteshami@gmail.com

**Contributions:** AG, EC, SA, take responsibility for the content and design of the manuscript; AG, EC, PG, contributed substantially to the writing of the manuscript; NK, RA, DR, proofread the article. All the authors have read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

**Conflict of interest:** the authors have no conflict of interest to declare.

**Ethics approval and consent to participate:** not applicable.

**Patient consent for publication:** not applicable.

**Funding:** none.

**Availability of data and materials:** not applicable.

## **Abstract**

This review presents a comprehensive examination of the contemporary landscape pertaining to latent tuberculosis infection (LTBI) diagnostics, with a particular emphasis on the global ramifications and the intricacies surrounding LTBI diagnosis and treatment. It accentuates the imperative of bolstering diagnostic, preventive, and treatment modalities for tuberculosis (TB) to fulfill the ambitious targets set forth by the World Health Organization aimed at reducing TB-related mortalities and the incidence of new TB cases. The document underscores the significance of addressing LTBI as a means of averting the progression to active TB, particularly in regions burdened with high TB prevalence, such as India. An in-depth analysis of the spectrum delineating latent and active TB disease is provided, elucidating the risk factors predisposing individuals with LTBI to progress towards active TB, including compromised immune functionality, concurrent HIV infection, and other immunosuppressive states. Furthermore, the challenges associated with LTBI diagnosis are elucidated, encompassing the absence of a definitive diagnostic assay, and the merits and demerits of tuberculin skin testing (TST) and interferon- $\gamma$  release assays (IGRAs) are expounded upon. The document underscores the necessity of confronting these challenges and furnishes a meticulous examination of the advantages and limitations of TST and IGRAs, along with the intricacies involved in interpreting their outcomes across diverse demographics and settings. Additionally, attention is drawn towards the heritability of the interferon- $\gamma$  response to mycobacterial antigens and the potential utility of antibodies in LTBI diagnosis.

**Key words:** infection, prevention, mantoux, interferon- $\gamma$  release assays.

## **Introduction**

Tuberculosis (TB) is a major public health problem worldwide. As per Global TB report 2023, globally 10.6 million people developed TB disease and about a quarter of the world's TB cases were reported from India in 2021 [1]. The WHO 'End TB strategy' aims to reduce TB deaths by 95% and lower the incidence of new TB cases by 90% between 2015 and 2035 [2]. To attain the worldwide goals for reducing the TB disease burden, it is imperative to enhance the diagnostic, preventive, and treatment services for tuberculosis [3,4].

Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by *Mycobacterium tuberculosis* antigens with no evidence of clinically manifest active TB. The exact global burden is not known due to lack of definitive diagnostic tests. One in four people in the world is estimated to have LTBI. The global prevalence of LTBI is estimated to be nearly 23% which amounts to 1.7 billion people as per latest estimates [4]. among the six high-burden countries within the South-East Asia region, India contributes significantly, accounting for 28 percent of the worldwide tuberculosis (TB) burden. Notably, India bears the highest global burden of TB infection (TBI). As per findings from the National TB Prevalence Survey conducted in 2021, the crude prevalence of TBI among individuals aged over 15 years was reported at 31.3 percent [5].

Although efforts to curb the TB burden have resulted in a decline in the disease burden both globally and in India, but to achieve the WHO targets, especially, in the high TB-burden countries like India, it is not only crucial to improve the diagnosis and treatment of active TB, but also to prevent the development of active TB. To achieve this, active contact-tracing, integrating TB and HIV control programs, addressing the key gaps in LTBI diagnosis and treatment may become useful approaches [6-8].

### **Spectrum of latent tuberculosis and active tuberculosis**

Latent and active TB disease are two dynamic parts of the immunological spectrum. Persons with LTBI are considered to be non-infectious and asymptomatic but bacilli may reactivate and later cause active TB disease. After initial infection 5–10% of those infected will develop active TB disease in their lifetime, usually within the first 5 years after initial infection [6]. This risk is much higher in those with HIV and young children, with a ~10% annual risk of reactivation. Under 1 year of age, 40% of LTBI children, 24% in children of 1–10 years and 16% in those between 11 and 15 years may develop active TB if latent TB is left untreated [9].

Identification and treatment of these LTBI persons can reduce the burden of active TB diseases which is one of the main goals of TB control programs globally. It has been estimated that if we were to treat just 14% of individuals with LTBI per year, this would reduce the TB incidence from 1280 cases per million recorded in 2010 to 20 cases per million by 2050, without any additional intervention [10]. Achieving 90% LTBI treatment coverage by 2025 is therefore one of the key milestones set up by WHO [2].

While the treatment of TBI plays a crucial role in preventing TB disease, it is often underappreciated. Nevertheless, it remains a significant component of India's National Strategic Plan 2017-25 to eliminate TB by 2025, five years ahead of the sustainable development goals. The Lancet Commission on TB underscores that efforts to diagnose and treat TB effectively would be ineffective without the inclusion of TB preventive treatment (TPT) in a comprehensive strategy. It is imperative to enhance the implementation of established interventions, such as the adoption of effective new regimens for TPT and ensure their swift and efficient scaling up.

### **Risk factors for active tuberculosis**

Several factors elevate the risk of individuals with latent tuberculosis infection (LTBI) progressing to active TB. Many of these factors are linked to compromised immune responses, including concurrent HIV infection, cancer, immunosuppressive therapy, renal transplantation, and diabetes. The significance of diabetes is particularly noteworthy, as its prevalence has been on the rise in regions with high TB prevalence, and diabetic individuals are approximately three times more susceptible to developing TB compared to non-diabetic individuals [11,12]. Moreover, certain factors are associated with specific aspects of the host's response, such as macrophage activation, maintenance of granuloma structure, CD4 T cells, CD8 T cells, interferon-gamma (IFN-g), and tumor necrosis factor-alpha (TNF-a) production, all of which are pivotal in controlling the pathogen during LTBI [13]. In recent times, studies utilizing whole-blood transcriptomic profiling have been conducted to identify distinct signatures capable of distinguishing between LTBI and active tuberculosis, as well as predicting varying treatment outcomes [14-16].

### **Diagnosis of latent tuberculosis**

Lack of gold standard test for diagnosis of latent tuberculosis infection (LTBI) remains major challenge in tuberculosis (TB) control. As per current WHO guidelines the test for LTBI is to be done when the risk of development of active disease is increased in specific high risk population like close contact of a person with TB or immunosuppressed individuals like case of young children in contact with those with active TB, people living with human immunodeficiency virus (HIV) infection, or persons because of medications or conditions such as uncontrolled diabetes and cancer [6]. Since the positive predictive value of LTBI

testing is low, screening for LTBI in persons who are healthy and have a low risk of progressing to active disease is not recommended [17]. Secondly, the balance of risk and benefit is also different in high-burden settings, where the risk of reinfection may be high and screening for LTBI will have a low negative predictive value but same is not true for children where, the risk-to-benefit ratio is more favorable than for adults [6,17].

### **Testing for latent tuberculosis infection**

With regard to acceptable methods of LTBI diagnosis, the latest WHO guidelines 2018 recommend the tuberculin skin test (TST) and Interferon (IFN- $\gamma$ ) gamma release assay (IGRA) as the two types of tests available for identification of LTBI [6].

#### ***Tuberculin skin testing***

It was developed by Koch in 1890 but the intradermal technique currently in use was described in 1912 by Charles Mantoux, a French physician [18]. The tuberculin most widely used is purified protein derivative, prepared according to the method described by Siebert, (PPD-S) from *M. tuberculosis*, which is derived from cultures of *M. tuberculosis*. Purified protein derivative-research tuberculin (PPD-RT) 23 with Tween 80 of strength 1 TU and 2 TU are standardized tuberculin's available in India supplied by the Bacillus Calmette-Guérin (BCG) vaccine Laboratory, Guindy, Chennai [18]. The TST is performed using the Mantoux technique [19], which consists of the intradermal injection of 5 tuberculin units (TU) of PPD-S purified protein derivative (PPD) or 2 TU PPD RT23 (both are equivalent). A delayed-type hypersensitivity reaction will occur within 48 to 72 h in a person who has cell-mediated immunity to tuberculin antigens. There will be localized induration of the skin at the injection site, which may be determined by inspection (from a side view against the light as well as by direct light) and by palpation [20]. For standardization, the diameter of induration should be measured transversely to the long axis of the forearm and recorded in millimeters by a trained health person [21]. Reading should be performed in a good light, with the forearm slightly flexed at the elbow. Erythema (redness) should not be measured. Various manufacturers produce PPD (Purified Protein Derivative) that conforms to the international standard (PPD-SI), and there are also commercial brands available under the US FDA standard PPD-S2, including Aplisol (manufactured by JHP Pharmaceuticals, Inc. in

Rochester, MI, USA) and Tubersol (manufactured by Sanofi Pasteur Limited in Swiftwater, PA, USA).

The immune response observed in the Tuberculin Skin Test (TST) has been the focus of numerous studies. These studies have revealed that biological variations among individuals, such as the following factors, can partly account for why some individuals exhibit strong TST responses while others show weak or no response at all. (Table 1) [22-24]

#### *Adverse effects*

Severe reaction to the test in form of ulceration, necrosis, vesicle, swelling and redness of the arm can occur on very rare occasion particularly in people who have had TB or been infected previously and in those who have previously had the BCG vaccine [25]. Local reactions such as regional lymphangitis and adenitis may also occur on rare occasions. Allergic reactions are also rare complications [25]. There are no chances of developing TB from the test as live bacteria is not used for the test.

#### *Interpretation of tuberculin reaction*

The interpretation is done on basis of risk-stratified cutoffs for the size of induration (5 mm, 10 mm, or 15 mm) [18,21,26]. (Table 2)

#### *Limitations*

False-positive and false-negative results can occur with TST which is the main limitation of this test. Similar antigens from environmental mycobacteria like *M. avium*, *M. fortuitum*, *M. kansasii* and *M. bovis* can give positive reaction [17,18]. Due to their ubiquitous nature, a large number of populations in many areas of the world have been exposed and sensitized to antigens of environmental mycobacteria, and due to this exposure, NTMs may not be clinically important reason for false-positive TST results, except in populations where sensitization with NTM is high like post TB sequelae, immunocompromised and cancer patients [27-30]. The impact of BCG on TST specificity depends on certain factors like when and how many doses of BCG is given. Impact on TST specificity is minimal if BCG is administered at birth or early infancy and can be ignored while interpreting the results. In contrast, if BCG is given after infancy and/or given multiple times (i.e., booster shots), then TST specificity is affected [29]. False-negative TST results may occur because of cutaneous

anergy (anergy is the inability to react to skin tests because of a weakened immune system) in certain patient population (e.g., immunosuppressed individuals due to medical conditions such as HIV infection or malnutrition or those taking immunosuppressive medications like cancer), recent TB infection (within 8-10 weeks of exposure), very old TB infection (many years), very young age (less than six months old), recent live-virus vaccination (e.g., measles and smallpox), and disseminated TB disease [18,31].

This may also occur due to preanalytical or analytical sources of test variability (e.g., improper tuberculin handling or placement or incorrect interpretation of test results) [31]. The inter- and intrareader variability in measurements of induration is also seen with TST which affects reproducibility of the test [32].

A repeat visit is required to read the test results after 48 to 72 hours. Prolonged follow-up is required to measure long-term ability of a positive TST to predict development of active TB. As per previous literature, the association between tuberculin reactivity and the risk of active TB is poor [33]. The various phenomenon like Immunologic recall of preexisting hypersensitivity to TB (i.e., boosting), conversions (i.e., new infection), and reversions (of positive results to negative) may lead to non-specific variability and make the interpretation of repeat testing's to be complicated [17,32]. Also, only standardized PPD is required which must be stored at optimum temperature [17].

Deniz and colleagues conducted a study involving 371 patients with chronic kidney disease, a population more vulnerable to tuberculosis infection and disease. Their findings revealed that elevated levels of parathormone (PTH) and the use of vitamin D treatment were associated with negative TST results, suggesting that these factors might induce a degree of immunosuppression [34].

In children, two noteworthy reports have proposed that helminth infestations could influence the outcomes of immunological tests used to assess *M. tuberculosis* infection [35]. Furthermore, the ratio of IFN-gamma to IL-10 may positively correlate with TST results, indicating the potential significance of the interplay between these two cytokines in TST reactivity [36]. Additionally, this latter report demonstrated that TST outcomes are impacted by BCG vaccination but not by exposure to non-tuberculosis mycobacteria [36].

In summary, TST results are influenced by a complex interplay of factors, including age, nutritional and immunological status, the duration between antigen exposure and test administration, BCG vaccination, immunosuppression, genetic background, and the



potential for cross-reactivity with environmental non-tuberculosis mycobacteria, and possibly other pathogens.

### *Advantages*

It has been used to diagnose latent TB for more than 100 years and the test has very low cost. It does not require any withdrawal of blood and can be used in outpatient clinic without requirement of any sophisticated lab.

Other next Generation Skin Test for Detection of Tuberculosis- C-TB and Diaskintest are novel skin tests designed to detect latent tuberculosis infection (LTBI) by utilizing specific Mycobacterium tuberculosis (MT) antigens, ESAT-6 and CFP-10, instead of the traditional tuberculin solution employed in the tuberculin skin test (TST). These tests boast higher specificity compared to TST and are unaffected by prior BCG vaccination or exposure to environmental mycobacteria [37].

### ***Interferon- $\gamma$ release assays***

The Interferon-Gamma Release Assay (IGRA) is a recent whole blood test developed to detect interferon-gamma (IFN-g) production by sensitized T cells upon in vitro stimulation with mycobacterial antigens. Specifically, the test utilizes mycobacterial antigens, including the early secretory antigenic target 6 (ESAT-6) and the 10-kDa culture filtrate protein (CFP-10). These antigens are encoded within the region of differentiation 1 (RD1) found in the genomes of *M. tuberculosis* and *Mycobacterium bovis* and are notably absent in *Bacillus Calmette-Guérin* vaccine (BCG) and the majority of environmental mycobacteria [38,39]. Consequently, IGRA results remain unaffected by both BCG vaccination and exposure to environmental mycobacteria.

T-cell interferon-gamma release assays (IGRAs) serve as an alternative immunodiagnostic approach to the Tuberculin Skin Test (TST) for detecting *M. tuberculosis* infection. IGRAs, which are in vitro whole-blood tests measuring the cell-mediated immune response. This specificity makes them more suitable for *M. tuberculosis* detection than the widely used purified protein derivative (PPD) for TST. However, some evidence of cross-reactivity between ESAT-6 and CFP-10 of *M. tuberculosis* and *M. leprae* exists [34,35].

Until 2015, only two commercially available types of assays were present: QuantiFERON-TB Gold Plus and QuantiFERON TB Gold In-Tube (QFT-GIT). These tests, which have

replaced QuantiFERON-TB (QFT) and QuantiFERON-Gold, are the latest generation of IGRA. The US Food and Drug Administration (FDA) approved QuantiFERON-TB Gold Plus in 2015 and QFT-GIT in 2007 as an aid for detecting latent *M. tuberculosis* infection. The tests quantify interferon-gamma (IFN- $\gamma$ ) released from sensitized lymphocytes in whole blood incubated overnight with PPD from *M. tuberculosis* and control antigens.

Both assays use peptides from the RD1 antigens ESAT-6 and CFP-10, as well as peptides from one additional antigen (TB7.7 [Rv2654c]), which is not an RD1 antigen, in an in-tube format. The results are reported as quantification of IFN- $\gamma$  in international units (IU) per milliliter. If the IFN- $\gamma$  response to TB antigens is above the test cutoff, an individual is considered positive for *M. tuberculosis* infection. QuantiFERON-TB Gold Plus has a higher sensitivity (98.9%) compared to QFT-GIT (97.9%), while both tests exhibit similar specificity. However, in resource-limited, high TB-burden settings, where cost and logistics are limiting factors, TST remains the preferred method for LTBI diagnosis. TST is still considered the most preferred method for LTBI diagnosis in resource-limited, high TB-burden settings, due to cost and logistical constraints associated with IGRA-based tests.

*T-SPOT.TB assay (Oxford Immunotec, Abingdon, United Kingdom)*

The T-SPOT.TB assay is also an enzyme-linked immunosorbent spot (ELISPOT) assay. T-SPOT.TB counts the number of antimycobacterial effector T cells, white blood cells that produce interferon-gamma, in a sample of blood. This gives an overall measurement of the host immune response against mycobacteria, which can reveal the presence of infection with *Mycobacterium tuberculosis*. Because this does not rely on production of a reliable antibody response or recoverable pathogen, the technique can be used to detect latent tuberculosis [40]. The test received FDA approval in 2008.

It is performed on separated and counted peripheral blood mononuclear cells (PBMCs) that are incubated with ESAT-6 and CFP-10 peptides. The result is reported as the number of IFN- $\gamma$ -producing T cells (spot-forming cells). If the spot counts in the TB antigen wells exceed a specific threshold relative to the negative-control wells, the individual is considered positive for *M. tuberculosis* infection. In a systematic review and meta-analysis by Diel et al. [41], the sensitivity of T-SPOT.TB was 98% and negative predictive value was 94% showing the effectiveness of this test in ruling out *M. tuberculosis* infection.

Furthermore, various studies have documented the heritability of the interferon-gamma (IFN-g) response to mycobacterial antigens, including ESAT-6. The percentage of heritability varied among the populations examined, with the highest heritability reported in South African subjects, particularly when studying sibling pairs. In this context, the estimated heritability of the IFN-g response to ESAT-6 was found to be 58% [42,43].

#### *Test characteristics: sensitivity and specificity, reproducibility for LTBI*

IGRAs have a specificity for LTBI diagnosis of 95% in settings with a low TB incidence, and specificity is not affected by BCG vaccination [17,44,45]. The sensitivity for the T-SPOT.TB assay appears to be higher than that for the QFT assay or TST (approximately 90%, 80%, and 80%, respectively). Sensitivity of IGRAs is decreased in HIV infection and in children [46]. NTMs infections have no effect on IGRAs [22]. However, infection with *M. marinum* or *M. kansasii*, which express ESAT-6 or CFP-10, may cause positive results in IGRAs, as with the TST [47].

Functional T-cell assays are highly susceptible to variability by numerous factors at multiple levels, including assay manufacturing, preanalytical processing, analytical testing, and immunomodulation. A systematic review on IGRA reproducibility in 2009, showed that variability was substantial, with magnitudes of within-subject IFN- $\gamma$  responses varying by up to 80% [48].

#### *Advantages*

They require fewer visits than TST for test completion and do not have cross-reactivity with BCG results. The test results are available within 24 to 48 hours, as previously mentioned they have less cross-reactivity than TST with nontuberculous mycobacteria [17].

#### *Limitations*

The test requires a withdrawal of blood which may be challenging in children. A well-equipped laboratory, with electricity and trained staff is needed. Cold chain needs to be maintained for transport of kits and reagents and for their storage. There is high likelihood of false-positive conversions during serial testing and reproducibility is affected by several preanalytical and analytical factors as well as manufacturing defects. Interpretation of serial

IGRAs is complicated by frequent conversions and reversions and a lack of consensus on optimal thresholds [17].

Similar to the challenges observed with the Tuberculin Skin Test (TST), the performance of Interferon-Gamma Release Assay (IGRA) tests can be influenced by various factors, primarily associated with compromised immune responses and technical considerations. For instance, the inclusion of interleukin-7 (IL-7) has been shown to enhance test positivity [49].

The clinical accuracy of IGRAs appears to be adversely affected in patients with immune-mediated inflammatory diseases (IMIDs), such as Crohn's disease, where immune cell function is suppressed [50]. Additionally, patients receiving immunomodulatory drugs like teriflunomide, which inhibits T-cell activation, may experience a change in QuantiFERON results from positive to negative, often accompanied by a marked reduction in interferon-gamma (IFN-g) [51]. Moreover, the administration of high doses of corticosteroids has been linked to a high proportion of indeterminate QuantiFERON TB Gold in-tube (QFT-GIT) results in individuals with rheumatoid arthritis and inflammatory bowel disease. Consequently, patients with these conditions should be tested with QFT-GIT prior to commencing steroid treatment [52].

Interestingly, in TB patients, the sensitivity of IGRA is not compromised by the presence of diabetes. In fact, the sensitivity of QuantiFERON TB Gold (QTF) was significantly higher in TB patients with diabetes compared to those without diabetes [53].

Furthermore, technical variations that can impact IGRA results encompass issues related to blood sampling (including time and volume), tube shaking, incubation or processing delays (which may affect cell viability in blood), incubation duration, analytical errors, and manufacturing defects [54].

#### *Application of interferon- $\gamma$ release assays*

Recent studies have assessed interferon- assays for various applications, such as

(1) Individuals with Suspected TB Disease- A negative result with IGRAs in HIV-infected persons, cannot reliably rule out active TB because of suboptimal sensitivity for active TB. Also, IGRAs also cannot distinguish between LTBI and active TB, and therefore the specificity of TB diagnosis will always be poor in countries with high TB burdens [6,55]. In children with suspected active TB, the ability IGRA alone is poor to rule in or rule out active

TB, hence, IGRAs should be used with other clinical data (chest X-ray findings, and history of contact) to support a diagnosis of active TB [17,56]

(2) Prognostic Value for Progression to Active TB- The currently available data show that the predictive value of IGRAs for progression to TB disease is low and slightly but not significantly higher than that of the TST. The data suggest that a majority (95%) of those with positive IGRA or TST results do not progress to TB disease during follow-up [17,41].

(3) Monitoring of Antituberculosis Therapy- Studies have shown no role of IGRAs in monitoring treatment responses in both active and latent TB [57,58].

### **Comparing TST and IGRA for the Diagnosis of Latent Tuberculosis Infection (LTBI)** (Table 3) [41,59-60]

While both the Tuberculin Skin Test (TST) and the Interferon-Gamma Release Assay (IGRA) are employed in clinical practice for diagnosing Latent Tuberculosis Infection (LTBI), it's important to note that they assess distinct aspects of the immune response that are particularly relevant in immunocompetent individuals.

Latency antigens hold the potential to serve as differentiators between Latent Tuberculosis Infection (LTBI) and active tuberculosis (TB).

Numerous research endeavors have been dedicated to identifying mycobacterial antigens that are naturally expressed during Latent Tuberculosis Infection (LTBI). It is important to distinguish between the terms "latency," which pertains to the state of the host, and "dormancy," which refers to the bacterial state during latency. Dormancy characterizes a reversible metabolic quiescence, representing a condition of reduced bacterial metabolic activity as the bacilli transition from a replicating to a non-replicating state. In this non-replicating state, mycobacterial cells can endure extended periods without replication, utilizing various immune-evading strategies [61,62]. Conditions that foster this low metabolic state include factors such as oxygen deprivation and fluctuations in nitric oxide levels.

The accumulation of evidence, although at times conflicting, linking specific latency antigens with cytokine responses has yielded the following observations: (Table 4) [63-65]

## **Contribution of antibodies in diagnosing LTBI**

A prevalent viewpoint in the medical field suggests that the role of the human antibody response against *M. tuberculosis* in protecting against tuberculosis (TB) is relatively limited, especially when compared to the significance of cell-mediated immunity. This perspective has been reinforced by two key observations: the presence of elevated antibody levels in individuals with active TB, implying that antibodies do not provide substantial protection [66], and the seemingly unchanged risk of TB reactivation in patients treated with rituximab, a human/mouse chimeric anti-CD20 antibody known to swiftly deplete normal CD20-expressing B cells [67].

However, emerging evidence indicates that as the metabolism of *M. tuberculosis* undergoes changes during the course of infection, the expression of immunodominant antigens should reflect these alterations. This, in turn, results in variations in the antibody profile between individuals with Latent Tuberculosis Infection (LTBI) and those with active TB. These distinctions in antibody profiles hold potential for diagnostic applications [68].

Several noteworthy observations include the following:

- Mycobacterial proteins with molecular weights of 36, 25, and 23 kDa, found in membrane vesicles, have been exclusively identified in the sera of TB patients, not in healthy controls. Additionally, the titers of these antibodies are lower in individuals with Latent Tuberculosis Infection (LTBI) [66].
- Immunization with BCG leads to the production of immunoglobulin G (IgG) antibodies against Ag85A, which have been linked to a reduced risk of developing active TB [69].
- LTBI individuals exhibit notably higher levels of specific IgG antibodies against the transmembrane protein Rv1733c when compared to TB patients [70]. Conversely, TB patients in endemic regions display significantly higher antibody levels against specific *M. tuberculosis* proteins in contrast to healthy individuals living in the same areas [70].
- Individuals with established LTBI demonstrate elevated plasma levels of anti-Rv2626c IgG compared to recently infected individuals and patients with active TB [71].

## **Identifying the onset of active tuberculosis progression**

The progression from Latent Tuberculosis Infection (LTBI) to active TB is influenced by various factors. These factors encompass aspects related to the bacteria, such as strain virulence and inoculum size, as well as host-related factors like the state of the immune

response, treatment with steroids, the use of biologic agents such as antibodies targeting tumor necrosis factor, solid organ or hematological transplantation, HIV infection, and the individual's age. Environmental factors like smoking and occupational exposure, particularly in healthcare workers, also play a role in this progression.

Furthermore, in the context of differentiating active TB from LTBI patients, a specific subset of PPD-specific CD4 T-cells has been identified, which secretes tumor necrosis factor-alpha (TNF- $\alpha$ ) but not interferon-gamma (IFN- $\gamma$ ) or interleukin-2 (IL-2). These cells possess a differentiated effector memory phenotype, characterized by the absence of CD45RA, CCR7, and CD127. This particular subset has shown promise as a useful marker for distinguishing individuals with active TB from those with LTBI [72]. Additionally, recent research involving the stimulation of blood cells from patients with active TB or LTBI using PPD or ESAT-6/CFP-10 revealed that the CD4<sup>+</sup>CD27<sup>-</sup>CCR4<sup>+</sup> T-cell subset was induced to a greater extent in subjects with active TB compared to those with LTBI. This suggests that investigating the expression of CD27 and CCR4 may hold potential as valuable immunodiagnostic markers for tuberculosis [73].

### **Policy statement and guidelines**

2018 WHO policy on the use of IGRAs states that either a tuberculin skin test (TST) or interferon-gamma release assay (IGRA) can be used to test for LTBI, however, the availability and affordability of the tests will determine which will be chosen by clinicians and programme managers [6]. IGRAs nor the TST should be used for the diagnosis of active TB [74]. IGRAs also cannot distinguish between LTBI and active TB, and therefore the specificity of TB diagnosis will always be poor in countries with high TB burdens [56,75], LTBI testing by TST or IGRA is not a requirement for initiating preventive treatment in people living with HIV or child household contacts aged < 5 years [6]. As per guidelines for programmatic management of TB preventive treatment (TPT) from India, all household contacts of pulmonary TB, if asymptomatic and age  $\geq$  5 years, should be given TPT, if they have positive IGRA/TST or unavailable with normal or unavailable chest x-ray after ruling out active TB. Also other high risk groups should have a negative symptom screening to rule out active TB and should only receive TPT if IGRA/TST is positive and CXR, if available, is normal [76].

## Way forward

Latent Tuberculosis Infection (LTBI) constitutes a concealed facet of the broader global health issue of tuberculosis (TB). Achieving a dependable diagnosis and effective treatment for individuals with LTBI is of utmost importance in TB control, as they harbor the potential to progress to active TB. The Tuberculin Skin Test (TST) has traditionally been the most widely used method for LTBI diagnosis due to its simplicity and the *in vivo* evidence it provides for anti-mycobacterial cellular immune responses. Nevertheless, it is compromised by false positives in BCG-vaccinated individuals. The introduction of Interferon-Gamma Release Assays (IGRAs) has improved specificity, and the new QFT-Plus version holds promise for distinguishing between active TB and LTBI. Despite these advancements, the quest for a reliable biomarker of LTBI and the assessment of drug therapy efficacy in LTBI patients remain ongoing challenges.

This review summarizes key strategies and proposed targets, or immunological markers developed over the past decade for distinguishing between LTBI and active TB and for evaluating the effectiveness of LTBI treatment. These strategies include analyzing cellular profiles, such as the proportion of TNF- $\alpha$ -only effector T cells with an effector memory phenotype (CD45RA<sup>+</sup>CCR7<sup>-</sup>CD127<sup>-</sup>), which has been associated with a higher risk of progressing to active TB in immunocompetent adults. Another approach involves investigating a diverse population of immature myeloid-derived suppressor cells (MDSCs), which have been linked to both active TB and recently acquired LTBI. Additionally, the cellular response to mycobacterial latency-associated antigens, particularly those encoded by the DosR regulon, has shown promise in identifying individuals with LTBI or active TB. Other potential candidates for differentiation include the specific antibody response to distinct *M. tuberculosis* antigens, the identification of specific miRNA, and molecular signatures observed in blood transcriptome analysis, particularly those related to IFN- $\gamma$  signaling. Challenges ahead encompass the validation of these tests across diverse populations and their suitability for low-income countries where TB remains a significant public health concern. Overcoming these challenges may herald a transformative approach to tackling the disease.



## Conclusions

Both TST and IGRAs are acceptable but both have advantages and disadvantages. There are situations where neither test is appropriate (e.g., active TB diagnosis in adults) and scenarios where both tests may be necessary to detect *M. tuberculosis* infection (e.g., immunocompromised populations), and there are scenarios where one test may be preferable to another. Both TST and IGRAs have reproducibility challenges. The ability of both IGRAs and TST is limited in regard to finding the benefactors from LTBI therapy. Neither of the tests can predict subsequent development of active TB in subjects with LTBI with affirmation. In resource-limited and high TB burden countries, TST should remain as the mainstay of LTBI testing due to low cost, ease of applicability, no requirement of technical expertise, sophisticated labs and vene puncture. In future, highly predictive and accurate biomarkers need to be identified which have minimal limitations. Although both tests are valuable screening tools, their results should never be used alone. Careful clinical evaluation with emphasis on risk stratification should always precede diagnostic and therapeutic modalities.

## References

1. World Health Organization. Global TB report 2022. Available from: <https://iris.who.int/bitstream/handle/10665/363752/9789240061729-eng.pdf?sequence=1>.
2. World Health Organization. The END TB strategy; 2015. Available from: <https://apps.who.int/iris/bitstream/handle/10665/331326/WHO-HTM-TB-2015.19-eng.pdf?sequence=1&isAllowed=y>. Accessed on:20/02/2023.
3. World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention. Tuberculosis preventive treatment. 2020. Available from: <https://iris.who.int/bitstream/handle/10665/331170/9789240001503-eng.pdf?sequence=1>.
4. World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4: treatment. Drug-susceptible tuberculosis treatment. 2022. Available from: <https://iris.who.int/bitstream/handle/10665/353829/9789240048126-eng.pdf?sequence=1>.
5. Indian Council of Medical Research, ICMR-National Institute for Research in Tuberculosis, Ministry of Health and Family Welfare, Government of India, Central TB Division and National Tuberculosis Elimination Programme, World Health Organization

India Office, State TB Cells of all States and Union Territories. National prevalence survey in India 2019-2021. Available from: <https://tbcindia.gov.in/showfile.php?lid=3659>. Accessed on: 20/02/2023.

6. Global Tuberculosis Programme. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. 2018. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK531235/>. Accessed on: 20/04/2020.

7. Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. *PLoS Med* 2016;13:e1002152.

8. Kyu HH, Maddison ER, Henry NJ, et al. Global, regional, and national burden of tuberculosis, 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. *Lancet Infect Dis* 2018;18:1329-49.

9. Saha S, Kumar A, Saurabh K, et al. Current status of treatment of latent tuberculosis infection in India. *Indian J Med Sci* 2020;71:54-9.

10. Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project. *JAMA* 1999;282:677-86.

11. Ayelign B, Negash M, Genetu M, et al. Immunological impacts of diabetes on the susceptibility of *Mycobacterium tuberculosis*. *J Immunol Res* 2019;2019:6196532.

12. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. *PLoS Med* 2008;5:e152.

13. Flynn JL, Chan J. Tuberculosis: latency and reactivation MINIREVIEW tuberculosis: latency and reactivation. *Infect Immunity* 2001;69:4195-201.

14. Berry MPR, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. *Nature* 2010;466:973-7.

15. Ottenhoff THM, Dass RH, Yang N, et al. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. *PLoS One* 2012;7:e45839.

16. Thompson EG, Du Y, Malherbe ST, et al. Host blood RNA signatures predict the outcome of tuberculosis treatment. *Tuberculosis (Edinb)* 2017;107:48-58.

17. Pai M, Riley LW, Colford JM. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. *Lancet Infect Dis* 2004;4:761-76.

18. Nayak S, Acharjya B. Mantoux test and its interpretation. *Indian Dermatol Online J* 2012;3:2-6.

19. Deck F, Guld J. The WHO tuberculin test. *Bull Int Union Tuberc* 1964;34:53-70.
20. Howard A, Mercer P, Nataraj HC, Kang BC. Bevel-down superior to bevel-up in intradermal skin testing. *Ann Allergy Asthma Immunol* 1997;78:594-6.
21. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. *Am J Respir Crit Care Med* 2000;161:S221-47.
22. Druszczynska M, Wlodarczyk M, Kielnierowski G, et al. CD14-159C/T polymorphism in the development of delayed skin hypersensitivity to tuberculin. *PLoS One* 2017;12:e0190106.
23. Babu S, Bhat SQ, Kumar NP, et al. Regulatory T cells modulate Th17 responses in tuberculin skin test positive (TST+) individuals. *J Infect Dis* 2010;201:20-31.
24. Cobat A, Gallant CJ, Simkin L, et al. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. *J Exp Med* 2009;206:2583-91.
25. Kim Y, Dawes-Higgs E, Zagarella S. Foreign body reaction involving a Mantoux test site. *Australas J Dermatol* 2005;46:169-71.
26. Jonas DE, Riley SR, Lee LC, et al. Screening for latent tuberculosis infection in adults: updated evidence report and systematic review for the US preventive services task force. *JAMA* 2023;329:1495-509.
27. Bierrenbach AL, Floyd S, Cunha SC, et al. A comparison of dual skin test with mycobacterial antigens and tuberculin skin test alone in estimating prevalence of *Mycobacterium tuberculosis* infection from population surveys. *Int J Tuberc Lung Dis* 2003;7:312-9.
28. Fine PE, Floyd S, Stanford JL, et al. Environmental mycobacteria in northern Malawi: implications for the epidemiology of tuberculosis and leprosy. *Epidemiol Infect* 2001;126:379-87.
29. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?. *Int J Tuberc Lung Dis* 2006;10:1192-204.

30. von Reyn CF, Horsburgh CR, Olivier KN, et al. Skin test reactions to *Mycobacterium tuberculosis* purified protein derivative and *Mycobacterium avium* sensitin among health care workers and medical students in the United States. *Int J Tuberc Lung Dis* 2001;5:1122-8.
31. Cohn DL. The effect of BCG vaccination on tuberculin skin testing. Does it matter?. *Am J Respir Crit Care Med* 2001;164:915-6.
32. Menzies D. Interpretation of repeated tuberculin tests: boosting, conversion, and reversion. *Am J Respir Crit Care Med* 1999;159:15-21.
33. Watkins RE, Brennan R, Plant AJ. Tuberculin reactivity and the risk of tuberculosis: a review. *Int J Tuberc Lung Dis* 2000;4:895-903.
34. Deniz S, Aydemir Y, Sengül A, et al. Factors affecting TST level in patients undergoing dialysis: a multicenter study. *Hemodial Int* 2019;23:81-7.
35. van Soelen N, Mandalakas AM, Kirchner HL, et al. Effect of ascaris lumbricoides specific IgE on tuberculin skin test responses in children in a high-burden setting: a cross-sectional community-based study. *BMC Infect Dis* 2012;12:211.
36. Burl S, Adetifa UJ, Cox M, et al. The tuberculin skin test (TST) is affected by recent BCG vaccination but not by exposure to non-tuberculosis mycobacteria (NTM) during early life. *PLoS One* 2010;5:e12287.
37. Zellweger JP, Sotgiu G, Corradi M, Durando P. The diagnosis of latent tuberculosis infection (LTBI): currently available tests, future developments, and perspectives to eliminate tuberculosis (TB). *Med Lav* 2020;111:170-83.
38. Arend SM, Geluk A, Van Meijgaarden KE, et al. Antigenic equivalence of human T-cell responses to *Mycobacterium tuberculosis*-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. *Infect Immun* 2000;68:3314-21.
39. Harboe M, Oettinger T, Wiker HG, et al. Evidence for occurrence of the ESAT-6 protein in *Mycobacterium tuberculosis* and virulent *Mycobacterium bovis* and for its absence in *Mycobacterium bovis* BCG. *Infect Immun* 1996;64:16-22.
40. T-SPOT.TB. The T-SPOT.TB test technology. Available from: <https://www.tspot.com/why-the-t-spot-tb-test/technology/>. Accessed on: 8/09/2020.

41. Diel R, Goletti D, Ferrara G, et al. Interferon- release assays for the diagnosis of latent *Mycobacterium tuberculosis* infection: a systematic review and meta-analysis. *Eur Respir J* 2011;37:88-99.
42. Cobat A, Gallant CJ, Simkin L, et al. High heritability of antimycobacterial immunity in an area of hyperendemicity for tuberculosis disease. *J Infect Dis* 2010;201:15-9.
43. Tao L, Zalwango S, Chervenak K, et al. Genetic and shared environmental influences on interferon-g production in response to mycobacterium tuberculosis antigens in a ugandan population. *Am J Trop Med Hyg* 2013;89:169-73.
44. Metcalfe JZ, Everett CK, Steingart KR, et al. Interferon- $\gamma$  Release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. *J Infect Dis* 2011;204:S1120-9.
45. Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, Migliori GB, et al. Interferon- $\gamma$  release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. *Eur Respir J* 2011;37:100-11.
46. Zwerling A, Pai M. The BCG world atlas: a new, open-access resource for clinicians and researchers. *Expert Rev Anti Infect Ther* 2011;9:559-61.
47. Arend SM, van Meijgaarden KE, de Boer K, et al. Tuberculin skin testing and in vitro t cell responses to esat-6 and culture filtrate protein 10 after infection with *Mycobacterium marinum* or *M. kansasii*. *J Infect Dis* 2002;186:1797-807.
48. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. *PLoS One* 2009;4:e8517.
49. Hiza H, Fenner L, Hella J, et al. Boosting effect of IL-7 in interferon gamma release assays to diagnose *Mycobacterium tuberculosis* infection. *PLoS One* 2018;13:e0202525.
50. Pérez I, Roig C, GilM, Torrent P, et al. Concordancia entre la prueba de la tuberculina y el interferon gamma release assay-IGRA en pacientes con enfermedades inflamatorias mediadas por la inmunidad. *Rev Española Quimioter* 2019;32:445-50.
51. Bua A, Ruggeri M, Zanetti S, Molicotti P. Effect of teriflunomide on QuantiFERON-TB gold results. *Med Microbiol Immunol* 2017;206:73-5.
52. Hakimian S, Popov Y, Rupawala AH, et al. The conundrum of indeterminate QuantiFERON-TB gold results before anti-tumor necrosis factor initiation. *Biol Targets Therapy* 2018;12:61-7.

53. Walsh MC, Camerlin AJ, Miles R, et al. The sensitivity of interferon-gamma release assays is not compromised in tuberculosis patients with diabetes. *Int J Tuberculosis Lung Dis* 2011;15:179-84.
54. Pai M, Behr M. Latent *Mycobacterium tuberculosis* infection and interferon-gamma release assays. *Microbiol Spectrum* 2016;4.
55. Dheda K, Smit R van Z, Badri M, Pai M. T-cell interferon- $\gamma$  release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings: *Curr Opin Pulm Med* 2009;15:188-200.
56. Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in hiv-infected individuals: a systematic review and meta-analysis. *J Acquir Immune Defic Syndr* 2011;56:230-8.
57. Denkinger CM, Pai M, Patel M, Menzies D. Gamma interferon release assay for monitoring of treatment response for active tuberculosis: an explosion in the spaghetti factory. *J Clin Microbiol* 2013;51:607-10.
58. Chiappini E, Fossi F, Bonsignori F, et al. Utility of interferon- $\gamma$  release assay results to monitor anti-tubercular treatment in adults and children. *Clin Ther* 2012;34:1041-8.
59. Pathakumari B, Devasundaram S, Raja A. Altered expression of antigenspecific memory and regulatory T-cell subsets differentiate latent and active tuberculosis. *Immunology* 2018;153:325-36.
60. Menzies D, Pai M, Zwerling A. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. *Ann Internal Med* 2008;149:177-84.
61. Caño-muñiz S, Anthony R, Niemann S, Alffenaar JC. New approaches and therapeutic options for mycobacterium. *Clin Microbiol Rev* 2018;31:e00060-17.
62. Lewis K. Persister cells. *Annu Rev Microbiol* 2010;64:357-72.
63. Goletti D, Butera O, Vanini V, et al. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. *Eur Respir J* 2010;36:135-42.
64. Chegou NN, Black GF, Loxton AG, et al. Potential of novel *Mycobacterium tuberculosis* infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting. *BMC Infect Dis* 2012;12:10.
65. Doddam SN, Peddireddy V, Ahmed N. *Mycobacterium tuberculosis* DosR regulon gene Rv2004c encodes a novel antigen with pro-inflammatory functions and potential diagnostic application for detection of latent tuberculosis. *Front Immunol* 2017;8:712.

66. Ziegenbalg A, Prados-Rosales R, Jenny-Avital ER, et al. Immunogenicity of mycobacterial vesicles in humans: Identification of a new tuberculosis antibody biomarker. *Tuberculosis (Edinb)* 2013;93:448-55.
67. Kimby E. Tolerability and safety of rituximab (MabTheraR ). *Cancer Treat Rev* 2005;31:456-73.
68. de Araujo LS, da Silva NBM, Leung JAM, et al. IgG subclasses' response to a set of mycobacterial antigens in different stages of *Mycobacterium tuberculosis* infection. *Tuberculosis* 2018;108:70-6.
69. Fletcher HA, Snowden MA, Landry B, et al. Tcell activation is an immune correlate of risk in BCG vaccinated infants. *Nat Commun* 2016;7:11290.
70. Coppola M, Arroyo L, van Meijgaarden KE, et al. Differences in IgG responses against infection phase related *Mycobacterium tuberculosis* (Mtb) specific antigens in individuals exposed or not to Mtb correlate with control of TB infection and progression. *Tuberculosis (Edinb)* 2017;106:25-32.
71. Amiano NO, Morelli MP, Pellegrini JM, et al. IFN-g and IgG responses to *Mycobacterium tuberculosis* latency antigen Rv2626c differentiate remote from recent tuberculosis infection. *Sci Rep* 2020;10:7472.
72. Pollock KM, Whitworth HS, Montamat-Sicotte DJ, et al. T-cell immunophenotyping distinguishes active from latent tuberculosis. *J Infect Dis* 2013;208:952-68.
73. Latorre I, Fernández-Sanmartín MA, Muriel-Moreno B, et al. Study of CD27 and CCR4 markers on specific CD4+ T-cells as immune tools for active and latent tuberculosis management. *Front Immunol* 2019;10:03094.
74. Weyer K, Gilpin C, Mirzayev F, et al. Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries: policy statement. 2011. Geneva, Switzerland: World Health Organization.
75. Pai M, Menzies D. Interferon- $\gamma$  RELEASE ASSAYS: WHAT IS THEIR ROLE IN THE DIAGNOSIS OF ACTIVE TUBERCULOSIS?. *Clin Infect Dis* 2007;44:74-7.
76. Ministry of Health and Family Welfare, Government of India. NTEP guidelines for programmatic management of TB preventive treatment in India. 2021. Available from: <https://tbcindia.gov.in/showfile.php?lid=3625>.

**Table 1. Summary of various immune markers and their influence on tuberculin skin test.**

Factor	Details
CD14 (-159C/T) Polymorphism [22]	- Associated with a higher likelihood of TST negativity
	- Observed even in individuals vaccinated with BCG
	- Variant found in the CD14 molecule within monocytes and macrophages.
Th1, Th2, or Th17 Immune Responses [23]	- TST reactivity influenced by Th1, Th2, or Th17 immune responses.
	- TST-positive individuals exhibit impaired production of IL-17 and IL-23.
	- Lack of Th17 upregulation is a significant characteristic of TST positivity.
	- Role of Th2 cytokines in TST reactivity may be less pronounced.
Delayed-Type Hypersensitivity (DTH) and TST2 Locus [24]	- Intensity of DTH response to tuberculin governed by TST2, a genetic locus.
	- TST2 located on chromosome region 5p15.
TST1 Locus on Chromosomal Region 11p14 [24]	- TST1 controls TST response.
	- Signifies resistance to M. tuberculosis independently of T-cell activity.
	- Located on chromosomal region 11p14.

CD14, cluster of differentiation 14; TST, Tuberculin skin test; BCG, Bacillus Calmette Guerin; Th, T helper cells; IL, interleukin; DTH, delayed type hypersensitivity.



**Table 2. Interpretation of tuberculin reaction.**

<b>Induration Size</b>	<b>Positive Result Criteria</b>	<b>Sensitivity[26]</b>	<b>Specificity[26]</b>
5 mm	<ul style="list-style-type: none"><li>- HIV-positive individuals.</li><li>- Recent contacts of active TB cases.</li><li>- Chest X-ray abnormalities consistent with old healed TB.</li><li>- Organ transplant recipients and other immunosuppressed patients.</li><li>- Patients on long-term corticosteroid therapy (&gt; 6 weeks) with prednisone dose 15 mg/day or equivalent.</li><li>- End-stage renal disease patients.</li></ul>	80%	95%
10 mm	<ul style="list-style-type: none"><li>- Recent arrivals ( 5 years) from high-prevalence countries.</li><li>- Injectable drug users.</li><li>- Residents and employees of high-risk congregate settings.</li><li>- Mycobacteriology lab personnel.</li><li>- Children &lt; 4 years, or those exposed to high-risk adults.</li><li>- Infants, children, and adolescents exposed to high-risk adults.</li></ul>	81%	98%
15 mm	<ul style="list-style-type: none"><li>- Individuals with no known TB risk factors; unlikely due to BCG vaccination or environmental mycobacteria exposure.</li></ul>	60%	99%

**Table 3. Comparison of tuberculin skin test and interferon- $\gamma$  release assay for the diagnosis of latent tuberculosis infection.**

Aspect	Details
<b>TST vs. IGRA for LTBI Diagnosis</b>	<p><b>TST:</b> - In vivo assessment of delayed-type hypersensitivity using purified protein derivative (PPD) from tuberculosis bacilli.</p> <p><b>IGRA:</b> - In vitro examination of the cell-mediated immune response, measuring interferon-gamma (IFN-g) production by circulating effector memory cells [57].</p>
<b>Antigen Diversity and Immune Response Variations</b>	<p>-Antigen diversity contributes to variations in specificity between TST and IGRA.</p> <p>-Genetic diversity and individual immune response differences impact test performance.</p> <p>-IGRA shows higher specificity in low-risk, BCG-vaccinated individuals and greater sensitivity in HIV-infected patients [58,59].</p>
<b>Discrepancies in Results and Test Accuracy</b>	<p>Discrepancies between TST and IGRA results are common in individuals with LTBI.</p> <p>- IGRA accuracy can be enhanced by extending the incubation period and measuring IL-2 levels, particularly QuantiFERON-GIT.</p>
<b>Involvement of T-Cell Subsets and Local Prevalence</b>	<p>- Positive results in both TST and IGRA associated with an increased number of regulatory T cells (CD4CD25 high CD39+ cells).</p> <p>- Correlation between TST and IGRA results varies based on regional tuberculosis incidence, BCG vaccination, environmental mycobacteria exposure, and risk of reinfection.</p>
<b>Limitations of TST and IGRA</b>	<p>- Low precision when screening immune-compromised individuals for LTBI.</p> <p>- Neither test highly effective in predicting the progression to active tuberculosis.</p>

TST, tuberculin skin test; IGRA, interferon- $\gamma$  release assay; LTBI, latent tuberculosis infection; IFN-g, interferon-gamma.

**Table 4. Summary of various antigen affecting immune response in latent tuberculosis and active tuberculosis.**

<b>Antigen</b>	<b>Immune Response in LTBI</b>	<b>Immune Response in Active TB</b>	<b>Comparison with Healthy Controls</b>
Rv2628 [61]	Higher IFN-g response in remote LTBI compared to recent infection	-	-
Rv2031c [61]	Lower IFN-g, TNF-a, and IL-10 in active TB compared to controls	Some studies found no differences in IFN-g response	-
DosR Antigens [62]	Disparities in IFN-g responses in healthy contacts vs. TB patients	-	Study involved multiple DosR antigens
Rv1737c, Rv2029c	Increased IFN-g or TNF-a-producing CD4 and CD8 T cells in LTBI	-	Stimulation of PBMC with specific antigens
RV2004 [63]	Robust proinflammatory response in LTBI vs. active TB and controls	-	Elevated TNF-a, IL-8, IL-1b, IL-12 levels
DosR Antigens [62]	Extensively studied antigens with potential for distinguishing LTBI from active TB	-	Rv0081, Rv1733c, Rv1737c, Rv2029c, Rv2031, Rv2628

LTBI, latent tuberculosis infection; IFN-g, interferon-gamma; IL, interleukin; TNF, tumor necrosis factor.